Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

International audienceABSTRACT: INTRODUCTION: The PACS01 trial has demonstrated that docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel benefit. METHODS: Tumor samples from 1.099 recruited women were analyzed for the expression of 34 selected proteins using immunohistochemistry. The prognostic and predictive values of each marker and four molecular subtypes (luminal A, luminal B, HER2-overexpressing, and triple-negative) were tested. RESULTS: Progesterone receptor-negativity (HR=0.66; 95%CI 0.47-0.92, P=0.013), and Ki67-positivity (HR=1.53; 95%CI 1.12-2.08, P=0.007) were independent adverse prognostic factors. Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR=0.51, 95%CI 0.33-0.79 for Ki67-positive versus HR=1.10, 95%CI 0.75-1.61 for Ki67-negative tumors, P for interaction=0.012). Molecular subtyping predicted the docetaxel benefit, but without providing additional information to Ki67 status. The luminal A subtype did not benefit from docetaxel (HR=1.16, 95%CI 0.73-1.84); the reduction in the relapse risk was 53% (HR=0.47, 95%CI 0.22-1.01), 34% (HR=0.66, 95%CI 0.37-1.19), and 12% (HR=0.88, 95%CI 0.49-1.57) in the luminal B, HER2-overexpressing, and triple-negative subtypes, respectively. CONCLUSIONS: In patients with node-positive EBC receiving adjuvant anthracycline-based chemotherapy, the most powerful predictor of docetaxel benefit is Ki67-positivity

Processus ponctuels et modèles markoviens (exemple d'application à une pathologie)

MONTPELLIER-BU Médecine UPM (341722108) / SudocPARIS-BIUP (751062107) / SudocMONTPELLIER-BU Médecine (341722104) / SudocSudocFranceF

Recherche des sites d'expression de la tolérance vis-à-vis de Xanthomonas campestris pathovar manihotis (Arthaud-Berthet) Starr chez certains cultivars de manioc (Manihot esculenta Crantz)

International audienc

Silicon/silicon oxide and silicon/silicon nitride multilayers for extreme ultraviolet

International audienc

Ti/TiN multilayers for hard coatings applications: in-situ characterization by real time spectroscopic ellipsometry

Single Ti and TiN, thick films and Ti/TiN, multilayers have been deposited by reactive rf-sputtering with in-situ control byspectroscopic ellipsometry. Spectroscopic ellipsometry allows one to measure precisely in real time the thickness of the depositedlayers after calibration of the optical indices of the materials. For multilayer deposition, the interdiffused layers can be followedin-situ and the interdiffusion mechanism can be understood. In this way, we have found that the interfaces of this system depositedby rf-sputtering are asymmetric. Different multilayer samples have been realized by varying the thickness of each component froml-10 nm with the same total thickness of stack (200 nm). Sliding wear tests were made to evaluate the wear lifetime of the samplesand to compare the results with those on simple thick films

New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials

International audienceImmunotherapy cancer clinical trials routinely feature an initial period during which the treatment is given without evident therapeutic benefit, which may be followed by a period during which an effective therapy reduces the hazard for event occurrence. The nature of this treatment effect is incompatible with the proportional hazards assumption, which has prompted much work on the development of alternative effect measures of frameworks for testing. We consider tests based on individual and combination of early- and late-emphasis infimum and supremum logrank statistics, describe how they can be implemented, and evaluate their performance in simulation studies. Through this work and illustrative applications we conclude that this class of test statistics offers a new and powerful framework for assessing treatment effects in cancer clinical trials involving immunotherapies

Tungsten/boron nitride multilayers for XUV optical applications

International audienc